BUR vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health scores paint a concerning picture, with a Piotroski F-Score of just 3/9 indicating weak financial health, and the absence of an Altman Z-Score prevents a full distress risk assessment. Despite strong profitability margins and a low Price/Book ratio, the company faces severe revenue contraction (YoY growth of -73.60%) and deeply negative earnings surprises, with 11 of the last 12 quarters missing or drastically underperforming estimates. While the stock trades below the Graham Number of $10.01, suggesting slight undervaluation, the weak fundamentals, deteriorating growth, and lack of insider support undermine this. The strong_buy analyst consensus appears overly optimistic given the deteriorating operational performance and bearish technical trend.
JPM shows bullish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Key strengths include strong valuation and growth metrics. Price trades at a 109.8% premium to fair value estimate ($140.21), limiting near-term upside from a valuation perspective.
Compare Another Pair
Related Comparisons
BUR vs JPM: Head-to-Head Comparison
This page compares Burford Capital Limited (BUR) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.